×

Advanced Life Sciences Announces Third Quarter 2010 Financial Results

CHICAGO, Nov. 12, 2010 /PRNewswire via COMTEX/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the third quarter ended September 30, 2010.

(Logo: http://photos.prnewswire.com/prnh/20080218/ALSLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO) "During the third quarter, we continued to implement our 'Restanza(TM) and Beyond' initiative by advancing the development of our hospital-focused Restanza IV formulation - a scientific breakthrough for the ketolide class," said Michael T. Flavin, Ph.D. Chairman and CEO. "In addition, we also strengthened our pipeline by establishing an agreement to develop antimicrobial peptides that kill troublesome Gram-negative pathogens. Gram-negative infections are highly lethal and, because of the increasing rate of resistance to current therapies, represent an urgent unmet medical need. In the coming months, we will continue to augment and advance our hospital-focused programs while seeking a government or pharmaceutical partnership to support the funding of the Restanza oral development program." The net loss allocable to common shareholders for the three months ended September 30, 2010 was $2.1 million or ($0.01) per share compared to a net loss allocable to common shareholders of $2.9 million or ($0.05) per share for the three months ended September 30, 2009. The decrease in the net loss is primarily due to reduced salary and benefit costs and other operating expenses associated with the development of the Company's lead antibiotic, Restanza.

Cash used for operating activities during the quarter was approximately $2.0 million. In the third quarter, the Company completed a securities offering raising approximately $1.6 million in gross proceeds and an additional $1.5 million in proceeds from the exercise of unit warrants issued in the offering.

The Company ended the third quarter of 2010 with cash and cash equivalents totaling $951,000.

Operating Expense Analysis Research and development expenses decreased by $0.2 million to approximately $0.7 million for the three months ended September 30, 2010 compared to $0.9 million for the three months ended September 30, 2009 due to lower government grant expenses associated with the Company's biodefense development program for Restanza.

Selling, general and administrative expenses were reduced to $1.2 million for the three months ended September 30, 2010 from $2.2 million during the third quarter of last year due to reduced salary and benefit costs and other operating expenses.

In October, the Company paid $420,000 in a principal reduction to its commercial bank toward a mandatory prepayment of $1.5 million that was due on October 1, 2010. The Company is engaged in substantive discussions with the bank regarding an agreement that would defer the balance of this prepayment to January of 2011.

Until agreement on such a deferral is reached or until the balance of the prepayment is made, however, the Company is subject to the default provisions of the loan documents including acceleration of payment.

Third Quarter and Recent Achievements Achieved an agreement with the U.S. Food & Drug Administration on the special protocol assessment (SPA) for Restanza in community acquired bacterial pneumonia (CABP) which provides a clear roadmap to approval; Awarded a $245,000 cash tax grant by the U.S. Internal Revenue Service through the Qualifying Therapeutic Discovery Project; Completed a public offering in the third quarter and received approximately $3.1 million in gross proceeds including the exercise of unit warrants issued as part of the offering; Entered into an agreement with YA Global Master SPV LTD. for the sale of up to $10.0 million of the Company's common stock over a two-year period. An effective S-1 registration statement has been established for the sale of up to 54 million shares; Reduced outstanding debt by $2.0 million in the third quarter by completing a debt-for-equity exchange and in October made a $0.4 million commercial loan principal payment to further reduce outstanding debt. In 2010, outstanding debt has been reduced by approximately $3.9 million; Presented Restanza biodefense data and exhibited at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Announced the publication of a research paper in the journal Bioorganic and Medicinal Chemistry Letters that reports data using the Company's core triterpenoid platform technology in the discovery and development of new cancer therapeutic agents; Submitted a full contract proposal in response to a Broad Agency Announcement (BAA) issued by the National Institutes of Allergy and Infectious Diseases (NIAID) for the development of Restanza in an IV formulation for the therapeutic treatment of multiple category A and B bacterial threats; Entered into a Cooperative Research and Development Agreement (CRADA) with The Walter Reed Army Institute of Research to allow the Institute to perform advanced animal efficacy testing of Restanza against various Plasmodium species that cause malaria.

Business Outlook and Goals for the Fourth Quarter of 2010 Advance discussions with prospective partners to support the Restanza Phase III SPA program initiation in CABP; Continue to identify government funding opportunities to support Restanza biodefense and CABP development programs for dual-use; Continue IND-directed development of the IV formulation of Restanza; Continue pursuit of Restanza FDA fast-track designation; Complete antimicrobial studies of cationic peptides as part of the University of British Columbia collaboration and report data; In-license additional value-enhancing pipeline candidates, especially those that would augment the Company's hospital-based respiratory focus.

Conference Call Details Advanced Life Sciences will host a conference call and live webcast at 9:00 a.m.

Eastern Time on Friday, November 12, 2010 to discuss the Company's third quarter financial results.

The conference call will be webcast simultaneously over the Internet. Please visit the Investor Relations section of the Advanced Life Sciences corporate website www.advancedlifesciences.com. Alternatively, callers may participate in the conference call by dialing 888.713.4214 (domestic) or 617.213.4866 (international). The passcode for the conference call is 88373836. A replay of the conference call will be available until November 19, 2010. Callers may access the telephone replay by dialing 888.286.8010 (domestic) or 617.801.6888 (international), passcode 91902424. Investors are advised to dial into the call at least ten minutes prior to the call to register. Participants may pre-register for the call at https://www.theconferencingservice.com/prereg/key.process?key.pro.

Pre-registrants will be issued a pin number to use when dialing into the live call which will provide quick access to the conference by bypassing the operator upon connection.

About Restanza Restanza is a novel, once-a-day, oral antibiotic that is in late stage development for the treatment of CABP and biodefense pathogens. It has shown higher in vitro potency and a broader range of activity than macrolides against Gram-positive bacteria associated with respiratory tract infections and appears to be effective against penicillin-, macrolide- and fluoroquinolone-resistant bacteria. Restanza's demonstrated potency and ability to overcome bacterial resistance may be due to its mechanism of action resulting in specificity for its bacterial target. In addition to its utility in CABP, Restanza is also being investigated for the prophylactic treatment of inhalation anthrax post-exposure and other high priority biodefense pathogens, including plague and tularemia.

The FDA has designated Restanza as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, as well as for use in treating plague and tularemia, but the drug is not yet approved for these or any other indications.

About Advanced Life Sciences Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CABP and biodefense pathogens including anthrax, plague and tularemia. For more information, please visit us on the web at www.advancedlifesciences.com or follow us on twitter at http://twitter.com/advancedlifesci.

Forward-Looking Statements Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our management's judgment regarding future events. The Company does not undertake any obligations to update any forward-looking statements whether as a result of new information, future events or otherwise. Our actual results could differ materially from those discussed herein due to several factors including the success and timing of our clinical trials and our ability to obtain and maintain regulatory approval and labeling of our product candidates; our plans to develop and commercialize our product candidates; the loss of key scientific or management personnel; the size and growth of potential markets for our product candidates and our ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of our estimates regarding expenses, future revenues and capital requirements; our ability to obtain financing on terms acceptable to us; our ability to obtain and maintain intellectual property protection for our product candidates; the successful development of our sales and marketing capabilities; the success of competing drugs that become available; and the performance of third party collaborators and manufacturers. These and additional risks and uncertainties are detailed in the Company's filings with the Securities and Exchange Commission.

ADVANCED LIFE SCIENCES HOLDINGS, INC. AND SUBSIDIARY (A Development Stage Company) September 30, December 31, CONSOLIDATED BALANCE SHEETS 2010 2009 (Unaudited) ASSETS CURRENT ASSETS: Cash and cash equivalents $950,840 $2,841,801 Grant receivable - 530,219 Prepaid insurance 44,226 111,761 Other prepaid expenses 33,950 88,535 ------ ------ Total current assets 1,029,016 3,572,316 --------- --------- PROPERTY AND EQUIPMENT: Furniture and fixtures 214,380 244,072 Computer software and equipment 258,786 258,786 Leasehold improvements 177,253 177,253 ------- ------- Total property and 650,419 680,111 equipment-at cost Less accumulated depreciation (620,046) (624,158) -------- -------- Property and equipment-net 30,373 55,953 ------ ------ OTHER ASSETS: Commercial launch materials 2,760,936 2,760,936 Deferred offering and financing costs 414,972 13,566 Other long-term assets 25,000 25,000 ------ ------ Total other assets 3,200,908 2,799,502 --------- --------- TOTAL ASSETS $4,260,297 $6,427,771 ========== ========== LIABILITIES AND EQUITY (DEFICIT) CURRENT LIABILITIES: Accounts payable $1,097,350 $604,334 Accrued payroll 553,401 664,436 Other accrued expenses 651,689 661,504 Accrued interest payable 60,208 73,194 Short-term lease payable - 4,350 Line of credit 2,500,000 - Short-term grant payable 500,000 ------- --- Total current liabilities 5,362,648 2,007,818 Long-term grant payable - 500,000 Long-term notes payable - related party - 2,000,000 Line of credit 6,000,000 10,000,000 --------- ---------- Total liabilities 11,362,648 14,507,818 ---------- ---------- COMMITMENTS AND CONTINGENCIES EQUITY (DEFICIT): Common stock, $0.01 par value-620,000,000 shares authorized; 224,090,841 issued and outstanding at September 30, 2010; 84,925,010 shares issued and outstanding at December 31, 2009 2,240,908 849,250 Additional paid-in capital 128,223,544 122,621,392 Deficit accumulated during the development stage (137,566,803) (131,550,689) Noncontrolling interest in subsidiary - - --- --- Total equity (deficit) (7,102,351) (8,080,047) ---------- ---------- TOTAL LIABILITIES AND EQUITY (DEFICIT) $4,260,297 $6,427,771 ========== ========== ADVANCED LIFE SCIENCES HOLDINGS, INC. AND SUBSIDIARY (A Development Stage Company) CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three months ended September 30, ------------------ 2010 2009 ---- ---- Revenue: Management fees $- $- Grants - 616,940 Royalty-related party --- --- Total revenue - 616,940 ------- Expenses: Research and development 662,278 916,241 Contracted research and development- related party - - Selling, general and administrative 1,167,230 2,201,684 --------- --------- Total expenses 1,829,508 3,117,925 --------- --------- Loss from operations (1,829,508) (2,500,985) Net other (income) expense: Interest income (1,573) (5,865) Interest expense 184,494 263,272 Other (income) expense, net - 99,854 Gain on sale of interest in Sarawak Medichem Pharmaceuticals joint venture --- --- Net other (income) expense 182,921 357,261 ------- ------- Net loss (2,012,429) (2,858,246) ---------- ---------- Less net loss attributable to the noncontrolling interest in subsidiary - - --- --- Net loss attributable to Advanced Life Sciences Holdings, Inc. (2,012,429) (2,858,246) ---------- ---------- Less accumulated preferred stock dividends of subsidiary for the period 43,750 43,750 ------ ------ Net loss available to common shareholders $(2,056,179) $(2,901,996) =========== =========== Net loss per share available to common shareholders -basic and diluted $(0.01) $(0.05) ====== ====== Weighted average shares outstanding - basic and diluted 182,022,584 62,715,539 Nine months ended September 30, ----------------- 2010 2009 ---- ---- Revenue: Management fees $- $- Grants 752,853 1,735,239 Royalty-related party --- --- Total revenue 752,853 1,735,239 ------- --------- Expenses: Research and development 2,280,470 3,160,061 Contracted research and development- related party - - Selling, general and administrative 3,802,818 5,401,142 --------- --------- Total expenses 6,083,288 8,561,203 --------- --------- Loss from operations (5,330,435) (6,825,964) Net other (income) expense: Interest income (8,136) (9,336) Interest expense 693,815 774,201 Other (income) expense, net - 119,449 Gain on sale of interest in Sarawak Medichem Pharmaceuticals joint venture --- --- Net other (income) expense 685,679 884,314 ------- ------- Net loss (6,016,114) (7,710,278) ---------- ---------- Less net loss attributable to the noncontrolling interest in subsidiary - - --- --- Net loss attributable to Advanced Life Sciences Holdings, Inc. (6,016,114) (7,710,278) ---------- ---------- Less accumulated preferred stock dividends of subsidiary for the period 131,250 131,250 ------- ------- Net loss available to common shareholders $(6,147,364) $(7,841,528) =========== =========== Net loss per share available to common shareholders -basic and diluted $(0.05) $(0.15) ====== ====== Weighted average shares outstanding - basic and diluted 125,339,679 50,601,036 Period From Inception (January 1, 1999) Through September 30, 2010 -------------- Revenue: Management fees $1,161,180 Grants 4,822,445 Royalty-related party 45,238 ------ Total revenue 6,028,863 --------- Expenses: Research and development 97,323,152 Contracted research and development- related party 7,980,299 Selling, general and administrative 37,174,304 ---------- Total expenses 142,477,755 ----------- Loss from operations (136,448,892) Net other (income) expense: Interest income (2,968,559) Interest expense 4,879,430 Other (income) expense, net 146,092 Gain on sale of interest in Sarawak Medichem Pharmaceuticals joint venture (939,052) -------- Net other (income) expense 1,117,911 --------- Net loss (137,566,803) ------------ Less net loss attributable to the noncontrolling interest in subsidiary - --- Net loss attributable to Advanced Life Sciences Holdings, Inc. (137,566,803) ------------ Less accumulated preferred stock dividends of subsidiary for the period 1,976,042 --------- Net loss available to common shareholders $(139,542,845) ============= Net loss per share available to common shareholders -basic and diluted Weighted average shares outstanding -basic and diluted SOURCE Advanced Life Sciences Holdings, Inc.

www.prnewswire.com Copyright (C) 2010 PR Newswire. All rights reserved -0- KEYWORD: Illinois INDUSTRY KEYWORD: HEA

MTC

OTC SUBJECT CODE: ERN

CCA